Monthly Archives: September 2012

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations
Journal of Commercial Biotechnology
ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate Plan Premium Plan Basic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Free Trial    Plan comparison    Site tour    Discount schedule    Contact

Drug Patent Expirations for August 14 2012

TradenameApplicantGeneric Name Patent Expiration
EXELONNovartisrivastigmineAug 14, 2012
EXELONNovartisrivastigmine tartrateAug 14, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Drug Patent Expirations for September 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
GEODON Pfizer Inc ziprasidone hydrochloride 5,312,925 Sep 1, 2012
GEODON Pfizer ziprasidone hydrochloride 5,312,925 Sep 1, 2012
BESIVANCE Bausch And Lomb besifloxacin hydrochloride 5,447,926 Sep 5, 2012
ALREX Bausch And Lomb loteprednol etabonate 4,996,335*PED Sep 9, 2012
ZYLET Bausch And Lomb loteprednol etabonate; tobramycin 4,996,335*PED Sep 9, 2012
LOTEMAX Bausch And Lomb loteprednol etabonate 4,996,335*PED Sep 9, 2012
EMEND Merck And Co Inc fosaprepitant dimeglumine 7,214,692 Sep 18, 2012
EMEND Merck aprepitant 7,214,692 Sep 18, 2012
EXFORGE Novartis amlodipine besylate; valsartan 5,399,578*PED Sep 21, 2012
DIOVAN Novartis valsartan 5,399,578*PED Sep 21, 2012
LATISSE Allergan bimatoprost 6,403,649 Sep 21, 2012
EXFORGE HCT Novartis amlodipine besylate; hydrochlorothiazide; valsartan 5,399,578*PED Sep 21, 2012
DIOVAN HCT Novartis hydrochlorothiazide; valsartan 5,399,578*PED Sep 21, 2012
LUMIGAN Allergan bimatoprost 6,403,649 Sep 21, 2012
SYMBICORT Astrazeneca budesonide; formoterol fumarate dihydrate 6,641,800 Sep 23, 2012
DETROL LA Pharmacia And Upjohn tolterodine tartrate 5,382,600*PED Sep 25, 2012
TIKOSYN Pfizer dofetilide 4,959,366 Sep 25, 2012
DETROL Pharmacia And Upjohn tolterodine tartrate 5,382,600*PED Sep 25, 2012
NIMBEX PRESERVATIVE FREE Abbvie cisatracurium besylate 5,453,510 Sep 26, 2012
NIMBEX Abbvie cisatracurium besylate 5,453,510 Sep 26, 2012
REVATIO Pfizer sildenafil citrate 5,250,534*PED Sep 27, 2012
VIAGRA Pfizer Ireland sildenafil citrate 5,250,534*PED Sep 27, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.